14 June 2024
14 June 2024
FutureGen is entitled to receive $1.56bn in milestone payments on meeting specified milestones.
Artificial intelligence (AI) has the potential to revolutionize drug development through improved efficiency, accuracy, and speed.
The autoinjector offers adults with moderate-to-severe atopic dermatitis an alternative administration method of Adbry.
Since its inception in 2022, Santa Ana has progressed three programmes, with clinical trials expected to begin in 2025.
Suven intends to purchase the remaining shares, ultimately owning 100% of Sapala Organics’ share capital.
After a successful trial, the UK NHS has become the first to permanently adopt a subscription payment model for new antibiotics.
The new guidelines outline ways to develop NHS-industry partnerships and follow the ABPI’s manifesto.
Two hepatitis B and coeliac disease candidates will be the priority for the company whilst a prostate cancer asset appears to be sidelined.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
